A Danish company is spending $145 million upfront for certain rights to the first-ever needle-free adrenaline nasal spray for severe allergic reactions, unlocking sales potential of more than $400 ...

The eye giant Alcon has launched an unlikely legal battle, suing a cell therapy startup that it invested in and claiming its shareholder rights are being violated as Aurion Biotech ...

Glucagon-like peptide-1 (GLP-1) receptor agonists have gained attention as potential treatments for a variety of ...

US regulators gave the green light to Autolus Therapeutics’ cell therapy for adult B-cell precursor acute lymphoblastic leukemia, or B-ALL, that has returned or is not responding to prior treatment ...